Antimicrobials · Fluoroquinolones
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, effectively halting DNA replication.
Moxifloxacin is a respiratory fluoroquinolone with enhanced activity against Streptococcus pneumoniae compared to ciprofloxacin.
Moxifloxacin carries a black box warning for tendon rupture, particularly involving the Achilles tendon in elderly patients or those on corticosteroids.
Moxifloxacin is associated with QT interval prolongation, increasing the risk of Torsades de Pointes in patients with pre-existing cardiac conduction abnormalities.
Moxifloxacin is generally avoided in pregnant women and children due to the risk of cartilage damage and arthropathy (seen in juvenile animals); its only labeled contraindication is hypersensitivity to any quinolone.
Moxifloxacin is unique among fluoroquinolones because it is primarily hepatically eliminated and does not require renal dose adjustment.
Fluoroquinolones carry a class phototoxicity warning, but moxifloxacin is among the least phototoxic agents in the class (no phototoxicity versus placebo in volunteer studies); patients should still be counseled to avoid excessive sunlight exposure.
Vignette unlocked
A 68-year-old male with a history of COPD presents with a productive cough, fever, and pleuritic chest pain. Physical examination reveals inspiratory crackles in the right lower lobe and a temperature of 101.4°F. His current medications include prednisone for COPD maintenance and lisinopril for hypertension. An EKG shows a QT interval of 480 ms. The patient is diagnosed with community-acquired pneumonia.
Which of the following antibiotics is most likely to exacerbate this patient's cardiac condition and should be avoided?
Moxifloxacin
The patient has a prolonged QT interval, and moxifloxacin is known to cause further QT prolongation, increasing the risk of Torsades de Pointes.
Full handout
High yield triage
Classification
4th generation Fluoroquinolone with enhanced anaerobic and Gram-positive coverage.
Indications
Community-acquired pneumonia, acute bacterial sinusitis, and intra-abdominal infections.
Mechanism of Action
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV to block bacterial DNA synthesis.
Side Effects
Nausea, diarrhea, tendon rupture, QT prolongation, and dysglycemia.
Contraindications / Monitoring
Avoid in myasthenia gravis (boxed warning); the only labeled contraindication is hypersensitivity to any quinolone. Monitor ECG for QT prolongation and watch for tendonitis.
Full handout
Mechanism of Action
Moxifloxacin acts as a bactericidal agent by inhibiting DNA gyrase (topoisomerase II) and topoisomerase IV. This dual inhibition prevents bacterial DNA replication and transcription. It is particularly effective against Streptococcus pneumoniae and various anaerobes due to its structural modifications.
Unique Properties
Unlike ciprofloxacin, moxifloxacin has superior activity against Gram-positive organisms and anaerobes. It is the only fluoroquinolone that does not require dose adjustment in renal impairment because it is primarily eliminated via the liver.
Indications
It is a first-line respiratory fluoroquinolone for community-acquired pneumonia (CAP) in patients with comorbidities. It is also labeled for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and complicated intra-abdominal infections — but per the FDA's 2016 safety communication, use for sinusitis and bronchitis exacerbations should be reserved for patients with no alternative treatment options.
Pharmacokinetics
Moxifloxacin undergoes extensive hepatic metabolism via glucuronidation and sulfation. It is not significantly cleared by the kidneys, making it safe for patients with renal failure. Avoid co-administration with cation-containing antacids or iron supplements to prevent chelation.
Side Effects & Adverse Events
Common effects include nausea and dizziness. Serious risks include tendon rupture (especially the Achilles tendon), QT prolongation leading to torsades de pointes, and dysglycemia (both hypo- and hyperglycemia). It may also cause Clostridioides difficile-associated diarrhea.
Contraindications
Myasthenia gravis appears in the boxed warning: fluoroquinolones may exacerbate muscle weakness and moxifloxacin should be avoided in patients with a known history of myasthenia gravis; the only formally labeled contraindication is hypersensitivity to any quinolone. Pregnancy and pediatric patients are generally avoided due to concerns regarding cartilage damage and arthropathy.
Monitoring
Perform baseline ECG in patients with risk factors for QT prolongation or those on concomitant antiarrhythmics. Monitor blood glucose levels in diabetic patients and assess for signs of tendonitis or peripheral neuropathy during therapy.
Clinical Pearls
Remember the 'Respiratory Fluoroquinolone' moniker for CAP coverage. If a board question asks for a fluoroquinolone in a patient with CKD, moxifloxacin is favored because it is hepatically cleared — but do not use moxifloxacin for UTIs due to poor urinary concentration.